<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285229</url>
  </required_header>
  <id_info>
    <org_study_id>16721</org_study_id>
    <secondary_id>I1F-MC-RHCH</secondary_id>
    <nct_id>NCT04285229</nct_id>
  </id_info>
  <brief_title>A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in&#xD;
      Chinese participants with radiographic axial spondyloarthritis (r-axSpA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 10, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of Participants Achieving an ASAS40 Response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ASAS20 Response</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of Participants Achieving an ASAS20 Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from Baseline in ASDAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Response</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from Baseline in BASDAI Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from Baseline in BASFI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from Baseline in MRI of the Spine (SPARCC Score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from Baseline in SF-36 PCS Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from Baseline in SF-36 MCS Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from Baseline in the Measure of High Sensitivity CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from Baseline in Mobility on the BASMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from Baseline in MASES</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from Baseline in MRI SIJ SPARCC Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anterior Uveitis</measure>
    <time_frame>Baseline through Week 16</time_frame>
    <description>Number of Participants With Anterior Uveitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from Baseline in ASAS-NSAID Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Ixekizumab Antibodies</measure>
    <time_frame>Baseline through Week 16</time_frame>
    <description>Number of Participants With Anti-Ixekizumab Antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)</measure>
    <time_frame>Baseline through Week 16</time_frame>
    <description>PK: Trough Ixekizumab Concentration at Steady State (Ctrough ss)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Ixekizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixekizumab given subcutaneously (SC) during the double-blind and extended treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given SC during the double-blind period and then ixekizumab will be given SC during the extended treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixekizumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Ixekizumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>LY2439821</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have an established diagnosis of radiographic axial spondyloarthritis (r-xSpA) with&#xD;
             sacroiliitis defined radiographically according to the modified New York criteria.&#xD;
&#xD;
          -  Participants have a history of back pain ≥3 months with age at onset &lt;45 years.&#xD;
&#xD;
          -  Biologic naïve or have had prior treatment with 1 tumor necrosis factor (TNF)&#xD;
             inhibitor.&#xD;
&#xD;
          -  Must have had an inadequate response to 2 or more NSAIDs at the therapeutic dose range&#xD;
             for a total duration of at least 4 weeks OR have a history of intolerance to NSAIDs.&#xD;
&#xD;
          -  Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have total ankylosis of the spine.&#xD;
&#xD;
          -  Have recently received a live vaccine within 12 weeks or have had a vaccination with&#xD;
             Bacillus Calmette-Guerin (BCG) within the past year.&#xD;
&#xD;
          -  Have an ongoing or serious infection within the last 12 weeks.&#xD;
&#xD;
          -  Have a compromised immune system.&#xD;
&#xD;
          -  Have any other serious and/or uncontrolled diseases.&#xD;
&#xD;
          -  Have either a current diagnosis or a recent history of malignant disease.&#xD;
&#xD;
          -  Have had major surgery within 8 weeks of baseline, or will require surgery during the&#xD;
             study.&#xD;
&#xD;
          -  Are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Afflilated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Hospital affiliated to Medical College of Shantou Univer</name>
      <address>
        <city>Shantou</city>
        <state>Guangzhou</state>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wu Han Tongji Hospital</name>
      <address>
        <city>Wuhan City</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZhuZhou Central Hospital</name>
      <address>
        <city>ZhuZhou</city>
        <state>Hunan</state>
        <zip>412007</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Baotou Medical College</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pingxiang People's Hospital</name>
      <address>
        <city>Pingxiang</city>
        <state>Jiangxi</state>
        <zip>337000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HuaShan Hospital Affiliated To Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Xinjiang Uygur Autonomous Region</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 1, 2021</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ankylosing spondylitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ixekizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

